Skip to main content

Table 1 Characteristics of the patient population subdivided by the polymorphisms in CYP2C19 and CYP2D6.

From: No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

  CYP2C19
EM
CYP2C19
IM + PM
P value CYP2D6
UM + EM
CYP2D6
IM + PM
P value
Age 55 (28-69) 57 (31-66) 0.80 56 (28-69) 56 (35-68) 0.5
β2-micro-globulin 3.7 (1.2-55.6) 4.9 (1.5-22.0) 0.09 4.1 (1.3-36.0) 3.7 (1.2-56.6) 0.9
Creatinine 1.1 (0.6-9.4) 1.3 (0.5-8.4) 0.03 1.1 (0.5-9.4) 1.1 (0.7-6.9) 0.8
Albumin 3.5 (0.3-5.3) 3.3 (1.6-5.3) 0.07 3.5 (0.3-5.2) 3.5 (0.3-5.0) 0.5
Durie-Salmon Stage       
I 29 (11%) 5 (7%) 0.4 10 (8%) 11 (11%) 0.5
II 62 (24%) 14 (19%)   25 (20%) 23 (23%)  
III 167 (65%) 54 (74%)   89 (72%) 64 (65%)  
ISS       
I 46 (25%) 8 (16%) 0.04 18 (22%) 21 (28%) 0.5
II 78 (42%) 15 (31%)   33 (41%) 24 (32%)  
III 60 (33%) 26 (53%)   30 (37%) 29 (39%)  
Sex       
male 149 (56%) 48 (66%) 0.2 68 (54%) 68 (67%) 0.04
female 116 (44%) 25 (34%)   59 (46%) 33 (33%)